Urology

Edited by: Steve Bunk W.J. Catalona, D.S. Smith, R.L. Wolfert, T.J. Wang, H.G. Rittenhouse, T.L. Ratliff, R.B. Nadler, "Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening," JAMA-Journal of the American Medical Association, 274:1214-20, 1995. (Cited in 89 papers through August 1997) LESS WORK: Measuring free PSA in serum in screening for prostate cancer will necessitate fewer biopsies than will measuring total PSA, says urologis

Steve Bunk
Oct 12, 1997

Edited by: Steve Bunk
W.J. Catalona, D.S. Smith, R.L. Wolfert, T.J. Wang, H.G. Rittenhouse, T.L. Ratliff, R.B. Nadler, "Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening," JAMA-Journal of the American Medical Association, 274:1214-20, 1995. (Cited in 89 papers through August 1997)


LESS WORK: Measuring free PSA in serum in screening for prostate cancer will necessitate fewer biopsies than will measuring total PSA, says urologist William Catalona.
Comments by William J. Catalona, Department of Surgery, Washington University School of Medicine, St. Louis

The main problem with the current method of broad-based prostate cancer screenings for older men, say critics in the medical community, is that too many false-positive readings result. This high rate prompts doctors to routinely order biopsies, which often come up negative. Biopsies are costly and uncomfortable, and carry the potential for infection, notes William J. Catalona, a urologist in...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?